跳至主要内容
临床试验/EUCTR2004-004596-11-ES
EUCTR2004-004596-11-ES进行中(未招募)不适用

Phase II Study of VELCADETM in patientswith extranodal marginal zone B-cell lymphoma ofMALT-type pretreated with more than one prior systemictherapy regimen (X05142)

International Extranodal Lymphoma Study Group0 个研究点目标入组 35 人开始时间: 2006年5月23日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
入组人数
35

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • 1. histologically proven diagnosis of marginal zone B-cell lymphoma of MALT type arisen at
  • any extranodal site
  • 2. any stage (Ann Arbor I-IV) (see Appendix B)
  • 3. relapsed or refractory disease pretreated with > 1 prior chemotherapy regimen and/or anti-
  • CD20 immunotherapy
  • 4. no evidence of histologic transformation to a high grade lymphoma
  • 5. measurable or evaluable disease
  • 6. age > 18 years
  • 7. full recovery from previous therapy, with life expectancy of at least 6 months
  • 8. ECOG performance status 0-2 (see Appendix C)
  • 9. for primary gastric localized H. pylori-positive disease at diagnosis:
  • a. persistent disease 1 year after documented H. pylori infection eradication
  • b. clinical, endoscopic (or histologic) evidence of progression at any time after H. pylori
  • infection eradication
  • 10. no prior chemotherapy, immunotherapy or radiotherapy in the last 6 weeks
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range

排除标准

  • 1. prior diagnosis of neoplasm within 5 years, except cervical intraepithelial neoplasia type 1 (CIN1) or localized non-melanomatous skin cancer
  • 2. other investigational drugs with 14 days before enrollment
  • 3. evidence of symptomatic central nervous system (CNS) disease
  • 4. severe impairment of bone marrow function (ANC <1.0x109/L, PLT <30x109/L within 14 days before enrollment), unless due to lymphoma involvement
  • 5. evidence of grade 2 peripheral neuropathy within 14 days before enrollment
  • 6. known hypersensitivity to bortezomib, boron or mannitol
  • 7. pregnant or lactating status, confirmation that the subject is not pregnant must be
  • established by a negative serum -human chorionic gonadotropin ( -hCG) pregnancy test result obtained during screening. Pregnancy testing is not required for post-menopausal or surgically sterilized women
  • 8. any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial

研究者

发起方
International Extranodal Lymphoma Study Group

相似试验

进行中(未招募)
1 期
Phase II Study of VELCADETM in patientswith extranodal marginal zone B-cell lymphoma ofMALT-type pretreated with one prior systemic therapyregimen (X05142)
EUCTR2004-004594-29-ESInternational Extranodal Lymphoma Study Group35
进行中(未招募)
不适用
Phase II study of VELCADE in patients with extranodal marginal zone B-cell lymphoma of MALT-type pretreated with one prior systemic therapy regimetreatment of extranodal marginal zone B-cell non Hodgkin lymphoma of MALT type with bortezomibMedDRA version: 14.1Level: PTClassification code 10015823Term: Extranodal marginal zone B-cell lymphoma (MALT type) recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2004-004594-29-ITINTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP (IELSG)35
进行中(未招募)
不适用
Phase II study of VELCADDE in patients with extranodal marginal zone B-cell lymphoma of MALT type pretreated with more than one prior systemiuc therapy regimetreatment of relapsed extranodal marginal zone B cell non Hodgkin lymphoma of MALT type with bortezomibMedDRA version: 9.1Level: LLTClassification code 10015823Term: Extranodal marginal zone B-cell lymphoma (MALT type) recurrent
EUCTR2004-004596-11-ITINTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP (IELSG)28
进行中(未招募)
1 期
A Phase 2 Study of VELCADE™ in Subjects with Relapsed or Refractory follicular B-cell LymphomaFollicular Lymphoma
EUCTR2005-000734-21-BEGroupe d'Etude des Lymphomes de l'Adulte (GELA)
进行中(未招募)
不适用
A Phase 2, Randomized Study of VELCADE® (bortezomib), Dexamethasone, and Thalidomide Versus VELCADE® (bortezomib), Dexamethasone, Thalidomide, and Cyclophosphamide in Subjects With Previously Untreated Multiple Myeloma Who are Candidates for Autologous Transplantation.
EUCTR2006-006050-10-CZJanssen-Cilag International NV, Turnhoutseweg 30, 2340 Beerse, Belgium97